MARKETS

S&P 500 7,376.86 +0.31% NASDAQ 24,579.42 +1.09% FTSE 100 10,673.94 0.00% NIKKEI 58,776 +2.33% BRENT $96.52 -1.83% GOLD $4,096.7 +0.53%

Delayed 15 min · 08:07 GMT

FLASH

Week ahead: US inflation and China’s trade data due Tuesday US adds 165,000 jobs in October, almost triple forecasts AI sell-off goes global: $2.5T wiped from Nasdaq 100 in a day Greece clears surveys and cable works for the €1.9 billion Cyprus power link Berkshire’s cash hits record $377B as Q3 buybacks reach $9.6B Moderna lifts 2026 growth outlook to 15–25% after 29% Q3 jump Panama’s $8.5B Bet: The Canal That Wants to Be More Than a Canal Microsoft reportedly winds down Oracle AI-computing deal; Oracle falls 4% Up 1,500, down 1,800: Wall Street’s wildest week since the 2025 tariff crash Fox closes $22B Roku takeover months ahead of schedule

Week ahead: US inflation and China’s trade data due Tuesday US adds 165,000 jobs in October, almost triple forecasts AI sell-off goes global: $2.5T wiped from Nasdaq 100 in a day Greece clears surveys and cable works for the €1.9 billion Cyprus power link Berkshire’s cash hits record $377B as Q3 buybacks reach $9.6B Moderna lifts 2026 growth outlook to 15–25% after 29% Q3 jump Panama’s $8.5B Bet: The Canal That Wants to Be More Than a Canal Microsoft reportedly winds down Oracle AI-computing deal; Oracle falls 4% Up 1,500, down 1,800: Wall Street’s wildest week since the 2025 tariff crash Fox closes $22B Roku takeover months ahead of schedule

Industries

Novo Nordisk lifts 2026 outlook as Wegovy pill sales hit DKK 5.4B

Novo beat expectations and raised its guidance for the second time this year on strong demand for its weight-loss pill. Its shares jumped more than 6% in early trading.

News | 4 November 2026

Novo Nordisk lifts 2026 outlook as Wegovy pill sales hit DKK 5.4B

Novo beat expectations and raised its guidance for the second time this year on strong demand for its weight-loss pill. Its shares jumped more than 6% in early trading.

Q3 adjusted operating profit rose 27% at constant currencies to DKK 31.7B. Wegovy pill sales reached DKK 5.39B, and the pill is now launched in eight markets.

Novo now sees 2026 adjusted sales and operating profit between -2% and +2%, up from -6% to 0%. Reported operating profit fell 9% on DKK 8.7B of impairments, and

Novo plans to cut US list prices for Wegovy and Ozempic to $675 from 1 Jan 2027.